bluebird bio Statistics
Share Statistics
bluebird bio has 9.79M
shares outstanding. The number of shares has increased by 1.08%
in one year.
| Shares Outstanding | 9.79M |
| Shares Change (YoY) | 1.08% |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | 1.46% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,379 |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 507.41K, so 5.18% of the outstanding
shares have been sold short.
| Short Interest | 507.41K |
| Short % of Shares Out | 5.18% |
| Short % of Float | 5.21% |
| Short Ratio (days to cover) | 1.6 |
Valuation Ratios
The PE ratio is -0.34 and the forward
PE ratio is -1.41.
bluebird bio's PEG ratio is
0.
| PE Ratio | -0.34 |
| Forward PE | -1.41 |
| PS Ratio | 0.96 |
| Forward PS | 0.1 |
| PB Ratio | -2.56 |
| P/FCF Ratio | -0.31 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for bluebird bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48,
with a Debt / Equity ratio of -11.36.
| Current Ratio | 0.48 |
| Quick Ratio | 0.28 |
| Debt / Equity | -11.36 |
| Debt / EBITDA | -2.28 |
| Debt / FCF | -1.36 |
| Interest Coverage | -11.98 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $337,931.45 |
| Profits Per Employee | $-970,625 |
| Employee Count | 248 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | 70K |
| Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by -83.44% in the
last 52 weeks. The beta is 0.33, so bluebird bio's
price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -83.44% |
| 50-Day Moving Average | 4.18 |
| 200-Day Moving Average | 8.88 |
| Relative Strength Index (RSI) | 36.39 |
| Average Volume (20 Days) | 412,514 |
Income Statement
In the last 12 months, bluebird bio had revenue of 83.81M
and earned -240.72M
in profits. Earnings per share was -24.84.
| Revenue | 83.81M |
| Gross Profit | -5.57M |
| Operating Income | -270.46M |
| Net Income | -240.72M |
| EBITDA | -156.82M |
| EBIT | -218.07M |
| Earnings Per Share (EPS) | -24.84 |
Full Income StatementBalance Sheet
The company has 62.3M in cash and 358.24M in
debt, giving a net cash position of -295.93M.
| Cash & Cash Equivalents | 62.3M |
| Total Debt | 358.24M |
| Net Cash | -295.93M |
| Retained Earnings | -4.5B |
| Total Assets | 460.23M |
| Working Capital | -166.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -260.02M
and capital expenditures -2.6M, giving a free cash flow of -262.62M.
| Operating Cash Flow | -260.02M |
| Capital Expenditures | -2.6M |
| Free Cash Flow | -262.62M |
| FCF Per Share | -27.1 |
Full Cash Flow StatementMargins
Gross margin is -6.65%, with operating and profit margins of -322.72% and -287.23%.
| Gross Margin | -6.65% |
| Operating Margin | -322.72% |
| Pretax Margin | -287.14% |
| Profit Margin | -287.23% |
| EBITDA Margin | -187.12% |
| EBIT Margin | -322.72% |
| FCF Margin | -313.36% |
